Instem PLC (AIM:INS) said it is continuing to make good progress in China with subsidiary Provantis receiving preclinical software solution suite orders for a significant number of additional licensed users from two long-standing customers.
Four new clients have also been added, the healthcare software group said, adding all the new orders were Software-as-a-Service (SaaS) subscriptions.
Instem will provide the new customers with solutions incorporating a range of modules across areas including general toxicology, clinical pathology, pathology and implementation services.
Phil Reason, Instem chief executive, said: "We are very pleased to achieve these contracts, demonstrating the strength of our long-standing client relationships, the continuing transition to SaaS, as well as momentum in securing new business.
“The two existing customers have been clients for over seven years, illustrating the long-term nature of our relationships and how Instem supports its clients' growth.”